About Jai Corp Limited

Jai Corp Limited, incorporated on June 06, 1985, is an India-domiciled manufacturing company with registered office at A-3, M.I.D.C. Industrial Area, Nanded, Maharashtra, and corporate office at Nariman Point, Mumbai. The company manufactures woven sacks/fabric, jumbo bags (FIBC), PP staple fibre, geotextiles, spun yarn, and undertakes production, processing and trading of CR coils/sheets, GP/GC coils/sheets, and HR coils/plates, with plastic processing accounting for 99.94% of turnover in FY 2024–25 and steel at 0.06%. Operations span 7 plants/operations and 2 offices in India, serving 13 states and exporting to 11 countries; exports contributed about 10.13% of turnover in FY 2024–25. The company had gross turnover of Rs 511.94 crore, EBITDA of Rs 93.44 crore, and profit of Rs 74.72 crore in FY 2024–25 on a standalone basis, with production in the tape woven products division at 39,425 MT and FOB exports of Rs 51.83 crore. Jai Corp holds stakes in infrastructure-related entities (Mumbai SEZ Ltd., Rewas Ports Ltd.) and develops real estate through subsidiaries; one wholly owned subsidiary, Swar Land Developers Limited, is developing an industrial estate near Mumbai, while overseas subsidiary Oasis Holding FZC earns rental income from labour accommodations in UAE. The group structure includes 21 subsidiaries and 2 associates as per BRSR, including Urban Infrastructure Venture Capital Limited and Oasis Holding FZC (75%) among subsidiaries, and Searock Developers FZC and Urban Infrastructure Holdings Private Limited as associates.

Jai Corp Limited Business Segment

• Manufacturing focus: Plastic Processing (woven sacks and fabric, jumbo bags, PP staple fibre, geotextiles) at 99.94% of turnover; Steel manufacturing/processing (CR, GP/GC, HR coils/sheets/plates) at 0.06% in FY 2024–25.

• Business performance: Tape Woven Products production rose 9.02% to 39,425 MT; gross turnover increased 11.82% to Rs 511.64 crore; net profit was Rs 65.98 crore in FY 2024–25; steel division reported turnover of Rs 0.30 crore and a loss of Rs 1.20 crore.

• Real estate/infrastructure interests: Progress in industrial estate sales via Swar Land Developers (profit ~Rs 0.09 crore) and continued engagement on port/SEZ projects through invested entities.

Business Segments (revenue mix)

• By product/vertical (FY 2024–25, standalone):
  • Plastic Processing — 99.94% of turnover

  • Steel — 0.06% of turnover

• By geography (FY 2024–25, standalone):
  • India — Rs 459.69 crore (89.9%)

  • International — Rs 51.95 crore (10.1%)
    These are derived from total turnover Rs 511.94 crore and exports contribution 10.13%, rounded to one decimal place.

Jai Corp Limited Key Management

• Anand Jain — Chairman

• Gaurav Jain — Managing Director and Chief Executive Officer

• Virendra Jain — Vice Chairman

• Dinesh D. Paliwal — Director-Works

• Deepak Ojha — Chief Financial Officer

• Ananjan Datta — Company Secretary

Latest Updates on Jai Corp Limited

• FY 2024–25 performance: Gross turnover up 11.82% to Rs 511.94 crore; EBITDA up 17.92% to Rs 93.44 crore; net profit up 38.65% to Rs 74.72 crore (standalone).

• Exports strategy: FOB exports rose 30.32% to Rs 51.83 crore on focus on high-value products; export volume 2,898.50 MT.

• Buyback: Completed equity share buyback; reductions recorded in securities premium and recognition of buyback tax and costs in FY 2024–25.

• Steel division update: No CR coil production due to weak demand; reported turnover Rs 0.30 crore and loss Rs 1.20 crore.

• Subsidiary progress: Swar Land Developers’ industrial estate Phases I–III completed and under disposal; Oasis Holding FZC rental income of Rs 7.70 crore in UAE.

• Governance/Audit: Standalone auditors issued unmodified opinions with key audit matters on inventory valuation; CARO notes no auditor resignation and adequate internal controls; BRSR compiled on a standalone basis.

CSR execution: Spent Rs 1.02 crore; initiatives include education sponsorships in DNH & DD, RO plants maintenance benefiting ~52,000 people, and 268 free blood units for Thalassemia/Sickle Cell patients.